uniQure (QURE) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$22.59
+0.2% on the day
-64.5% over 12 months
52-week range $9.03 – $70.59
Share price and insider trades
QURE closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$22.1M
Insiders buying0
Insiders selling12
uniQure insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 12 sold $22.1M of QURE stock on the open market.
Get emailed when insiders cluster-buy stocks like QURE
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
QURE insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $952K | 3 |
| Q2 2026 | — | 0 | $17.0M | 35 |
| Q1 2026 | — | 0 | $2.1M | 14 |
| Q4 2025 | — | 0 | $2.0M | 5 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 uniQure N.V. insiders reported open-market purchases totaling $0, while 12 insiders reported sales totaling $22.1M. 38 of 57 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 7SEC | Matthew C KapustaCEO | Sell Plan | 9,200531,109 held (−2%) | $44.43 | $409K | -49.2% | — |
| Jul 7SEC | Matthew C KapustaCEO | Sell Plan | 7,600519,227 held (−1%) | $45.89 | $349K | -50.8% | — |
| Jul 7SEC | Matthew C KapustaCEO | Sell Plan | 4,282526,827 held (−1%) | $45.43 | $195K | -50.3% | — |
| Jul 2SEC | Walid Abi-saabChief Medical Officer | Sell Plan | 20,000148,235 held (−12%) | $46.40 | $928K | -51.3% | — |
| Jul 2SEC | Jack KayeDirector | Sell Plan | 17,06025,996 held (−40%) | $46.43 | $792K | -51.3% | — |
| Jul 2SEC | Walid Abi-saabChief Medical Officer | Sell Plan | 10,000168,235 held (−6%) | $46.46 | $465K | -51.4% | — |
| Jul 2SEC | Jack KayeDirector | Sell Plan | 4,10725,996 held (−14%) | $46.49 | $191K | -51.4% | — |
| Jun 30SEC | Walid Abi-saabChief Medical Officer | Sell | 1,434168,235 held (−1%) | $46.86 | $67K | -51.8% | — |
| Jun 26SEC | Matthew C KapustaCEO | Sell Plan | 28,716519,227 held (−5%) | $50.02 | $1.4M | -54.8% | — |
| Jun 26SEC | Matthew C KapustaCEO | Sell Plan | 6,696519,227 held (−1%) | $50.00 | $335K | -54.8% | — |
| Jun 22SEC | Matthew C KapustaCEO | Sell Plan | 56,929603,729 held (−9%) | $43.43 | $2.5M | -48.0% | — |
| Jun 22SEC | Matthew C KapustaCEO | Sell Plan | 37,015521,795 held (−7%) | $50.00 | $1.9M | -54.8% | — |
| Jun 22SEC | Matthew C KapustaCEO | Sell Plan | 33,334570,395 held (−6%) | $45.01 | $1.5M | -49.8% | — |
| Jun 22SEC | Matthew C KapustaCEO | Sell Plan | 32,581660,658 held (−5%) | $45.02 | $1.5M | -49.8% | — |
| Jun 22SEC | Matthew C KapustaCEO | Sell Plan | 23,977699,262 held (−3%) | $42.61 | $1.0M | -47.0% | — |
| Jun 22SEC | Matthew C KapustaCEO | Sell Plan | 11,585558,810 held (−2%) | $48.65 | $564K | -53.6% | — |
| Jun 22SEC | Matthew C KapustaCEO | Sell Plan | 6,023693,239 held (−1%) | $43.70 | $263K | -48.3% | — |
| Jun 22SEC | Madhavan BalachandranDirector | Sell Plan | 5,29549,644 held (−10%) | $47.08 | $249K | -52.0% | — |
| Jun 22SEC | Matthew C KapustaCEO | Sell Plan | 4,656558,810 held (−1%) | $50.00 | $233K | -54.8% | — |
| Jun 22SEC | Jack KayeDirector | Sell Plan | 5,29525,996 held (−17%) | $42.57 | $225K | -46.9% | — |
| Jun 22SEC | Madhavan BalachandranDirector | Sell Plan | 4,70044,944 held (−9%) | $43.66 | $205K | -48.3% | — |
| Jun 22SEC | Madhavan BalachandranDirector | Sell Plan | 1,69043,254 held (−4%) | $42.60 | $72K | -47.0% | — |
| Jun 17SEC | Madhavan BalachandranDirector | Sell Plan | 10,00043,254 held (−19%) | $27.85 | $278K | -18.9% | — |
| Jun 17SEC | Jeannette PottsGeneral Counsel | Sell | 5,237133,246 held (−4%) | $27.67 | $145K | -18.4% | — |
| Jun 12SEC | Kylie O'keefeChief Customer & Strat Officer | Sell | 15,936108,864 held (−13%) | $27.06 | $431K | -16.5% | — |
| Jun 12SEC | Robert GutDirector | Sell Plan | 3,12729,215 held (−10%) | $26.03 | $81K | -13.2% | — |
| Jun 12SEC | Robert GutDirector | Sell Plan | 2,72632,259 held (−8%) | $27.06 | $74K | -16.5% | — |
| Jun 12SEC | Robert GutDirector | Sell Plan | 2,64532,342 held (−8%) | $26.07 | $69K | -13.3% | — |
| Jun 12SEC | David D. MeekDirector | Sell | 1,99339,747 held (−5%) | $27.06 | $54K | -16.5% | — |
| Jun 12SEC | Rachelle Suzanne JacquesDirector | Sell | 1,99333,903 held (−6%) | $27.06 | $54K | -16.5% | — |
| Jun 12SEC | Leonard E PostDirector | Sell | 1,99335,494 held (−5%) | $27.06 | $54K | -16.5% | — |
| Jun 12SEC | Madhavan BalachandranDirector | Sell | 1,99343,254 held (−4%) | $27.06 | $54K | -16.5% | — |
| Jun 12SEC | Jack KayeDirector | Sell | 1,99325,996 held (−7%) | $27.06 | $54K | -16.5% | — |
| Jun 12SEC | Jeremy P. SpringhornDirector | Sell | 1,99343,251 held (−4%) | $27.06 | $54K | -16.5% | — |
| Jun 12SEC | Robert GutDirector | Sell Plan | 1,78027,435 held (−6%) | $26.05 | $46K | -13.3% | — |
| Jun 5SEC | Jack KayeDirector | Sell Plan | 2,64520,439 held (−11%) | $30.01 | $79K | -24.7% | — |
| May 12SEC | Walid Abi-saabChief Medical Officer | Sell Plan | 25,000189,669 held (−12%) | $25.10 | $628K | -10.0% | — |
| May 12SEC | Walid Abi-saabChief Medical Officer | Sell Plan | 20,000169,669 held (−11%) | $25.00 | $500K | -9.6% | — |
| Mar 6SEC | Matthew C KapustaCEO | Sell | 14,581660,658 held (−2%) | $9.06 | $132K | +149.3% | — |
| Mar 6SEC | Christian KlemtCFO | Sell | 12,000226,581 held (−5%) | $9.06 | $109K | +149.3% | — |
| Mar 6SEC | Jeannette PottsGeneral Counsel | Sell | 3,412138,483 held (−2%) | $9.06 | $31K | +149.3% | — |
| Mar 6SEC | Walid Abi-saabChief Medical Officer | Sell | 808189,669 held (−0%) | $9.06 | $7K | +149.3% | — |
| Mar 4SEC | Matthew C KapustaCEO | Sell | 34,437604,639 held (−5%) | $9.95 | $343K | +127.0% | — |
| Mar 4SEC | Christian KlemtCFO | Sell | 12,532198,981 held (−6%) | $9.95 | $125K | +127.0% | — |
| Mar 4SEC | Jeannette PottsGeneral Counsel | Sell | 8,578106,495 held (−7%) | $9.95 | $85K | +127.0% | — |
| Mar 4SEC | Walid Abi-saabChief Medical Officer | Sell | 1,660148,777 held (−1%) | $9.95 | $17K | +127.0% | — |
| Feb 27SEC | Matthew C KapustaCEO | Sell | 12,378639,076 held (−2%) | $23.86 | $295K | -5.3% | — |
| Feb 27SEC | Christian KlemtCFO | Sell | 6,217211,513 held (−3%) | $23.86 | $148K | -5.3% | — |
| Jan 14SEC | Robert GutDirector | Sell Plan | 17,31040,645 held (−30%) | $24.39 | $422K | -7.4% | — |
| Jan 14SEC | Robert GutDirector | Sell Plan | 7,80332,342 held (−19%) | $25.09 | $196K | -10.0% | — |
| Jan 14SEC | Robert GutDirector | Sell Plan | 50040,145 held (−1%) | $25.03 | $13K | -9.7% | — |
| Jan 12SEC | Jack KayeDirector | Sell Plan | 6,39020,439 held (−24%) | $27.28 | $174K | -17.2% | — |
| Nov 10SEC | Robert GutDirector | Sell Plan | 15,84055,739 held (−22%) | $27.22 | $431K | -17.0% | — |
| Nov 10SEC | Robert GutDirector | Sell Plan | 15,59440,145 held (−28%) | $27.30 | $426K | -17.3% | — |
| Nov 6SEC | Jack KayeDirector | Sell Plan | 17,81020,439 held (−47%) | $30.33 | $540K | -25.5% | — |
| Nov 6SEC | Jack KayeDirector | Sell Plan | 11,00020,439 held (−35%) | $30.34 | $334K | -25.5% | — |
| Nov 6SEC | Jack KayeDirector | Sell Plan | 10,00020,439 held (−33%) | $30.36 | $304K | -25.6% | — |
Insiders at uniQure N.V.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Matthew C KapustaCEO | — | $12.9M | Jul 7, 2026 | — |
| Jack KayeDirector | — | $2.7M | Jul 2, 2026 | — |
| Walid Abi-saabChief Medical Officer | — | $2.6M | Jul 2, 2026 | — |
| Robert GutDirector | — | $1.8M | Jun 12, 2026 | — |
| Madhavan BalachandranDirector | — | $859K | Jun 22, 2026 | — |
| Kylie O'keefeChief Customer & Strat Officer | — | $431K | Jun 12, 2026 | — |
| Christian KlemtCFO | — | $382K | Mar 6, 2026 | — |
| Jeannette PottsGeneral Counsel | — | $261K | Jun 17, 2026 | — |
| David D. MeekDirector | — | $54K | Jun 12, 2026 | — |
| Rachelle Suzanne JacquesDirector | — | $54K | Jun 12, 2026 | — |
| Leonard E PostDirector | — | $54K | Jun 12, 2026 | — |
| Jeremy P. SpringhornDirector | — | $54K | Jun 12, 2026 | — |
QURE stock: common questions
Are uniQure N.V. insiders buying QURE stock?
In the past 12 months, 0 insiders reported open-market purchases of QURE worth $0.
Are uniQure N.V. insiders selling QURE stock?
12 insiders reported sales worth $22.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is QURE's 52-week range?
Over the past year QURE has traded between $9.03 and $70.59. It last closed at $22.59 on Oct 9, 2026.